Published in Virology on July 06, 2012
Exosomes from HIV-1-infected Cells Stimulate Production of Pro-inflammatory Cytokines through Trans-activating Response (TAR) RNA. J Biol Chem (2015) 0.90
Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol (2012) 0.89
Targeting HIV transcription: the quest for a functional cure. Curr Top Microbiol Immunol (2015) 0.85
Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol (2013) 0.79
The role of IKKβ in Venezuelan equine encephalitis virus infection. PLoS One (2014) 0.78
Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells. J Neurovirol (2015) 0.75
Evolutionary distance of amino acid sequence orthologs across macaque subspecies: identifying candidate genes for SIV resistance in Chinese rhesus macaques. PLoS One (2015) 0.75
Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy. World J Virol (2015) 0.75
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct Mol Biol (2008) 3.86
HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell (2010) 3.49
Tackling Tat. J Mol Biol (1999) 3.13
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell (2010) 2.91
Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol (2000) 2.65
The multi-tasking P-TEFb complex. Curr Opin Cell Biol (2008) 2.53
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A (1997) 2.52
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med (2002) 2.13
Crosstalk between mRNA 3' end processing and transcription initiation. Mol Cell (2010) 1.89
Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med (2012) 1.88
NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci (2008) 1.74
A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. EMBO J (1999) 1.73
DSIF, the Paf1 complex, and Tat-SF1 have nonredundant, cooperative roles in RNA polymerase II elongation. Genes Dev (2009) 1.64
Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene (1998) 1.57
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology (2007) 1.48
CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol (2003) 1.42
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol (2001) 1.40
New developments in anti-HIV chemotherapy. Biochim Biophys Acta (2002) 1.40
Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome. Mol Cell Biol (2001) 1.40
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS (2002) 1.40
HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci (2008) 1.37
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J Virol (2004) 1.30
Tat-SF1 protein associates with RAP30 and human SPT5 proteins. Mol Cell Biol (1999) 1.27
Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology (2006) 1.25
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology (2002) 1.22
Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. Cell Cycle (2009) 1.21
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Electroporation of viral transactivator proteins into lymphocyte suspension cells. Nucleic Acids Res (1992) 1.20
Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem (2004) 1.17
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem (2008) 1.17
The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci U S A (2003) 1.13
Two-step cross-linking for analysis of protein-chromatin interactions. Methods Mol Biol (2012) 1.06
Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol (2006) 1.06
Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter. J Virol (1998) 1.06
Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses (2009) 1.06
HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J (2002) 1.05
A new human immunodeficiency virus type 1 circulating recombinant form from Tanzania. AIDS Res Hum Retroviruses (2001) 1.04
Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol (2005) 1.03
Regulation of human immunodeficiency virus infection: implications for pathogenesis. Adv Virus Res (1994) 1.00
Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses (2009) 0.99
RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology (2005) 0.99
CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing. J Virol (2008) 0.99
Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat (2010) 0.95
Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther (2010) 0.92
Inhibition of HIV-1 virus replication using small soluble Tat peptides. Virology (2005) 0.92
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep (2004) 0.92
Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem (2010) 0.89
The transcriptional transactivator Tat selectively regulates viral splicing. Nucleic Acids Res (2009) 0.88
Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res (2003) 0.88
Tat-SF1 is not required for Tat transactivation but does regulate the relative levels of unspliced and spliced HIV-1 RNAs. PLoS One (2009) 0.88
P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes. J Biol Chem (2010) 0.87
HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells. J Biol Chem (2009) 0.85
microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. J RNAi Gene Silencing (2010) 0.85
Phosphorylation of histone H1 by P-TEFb is a necessary step in skeletal muscle differentiation. J Cell Physiol (2012) 0.77
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med (2005) 4.31
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol (2007) 2.20
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica (2006) 2.04
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. Bioorg Med Chem (2006) 1.81
Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell (2002) 1.76
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem (2004) 1.72
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One (2010) 1.63
Tat gets the "green" light on transcription initiation. Retrovirology (2005) 1.61
FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics (2008) 1.60
SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J Biol Chem (2003) 1.56
Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study. Sex Transm Infect (2012) 1.48
1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett (2004) 1.47
Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol (2003) 1.45
Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology (2008) 1.45
Degradation of Hof1 by SCF(Grr1) is important for actomyosin contraction during cytokinesis in yeast. EMBO J (2005) 1.44
Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J Biol Chem (2001) 1.42
The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology (2009) 1.42
Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin. Retrovirology (2006) 1.39
Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology (2006) 1.36
HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology (2009) 1.35
Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. J Biol Chem (2002) 1.34
Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res (2008) 1.34
Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes. J Biol Chem (2007) 1.33
Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. J Biol Chem (2013) 1.31
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J Virol (2004) 1.30
Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology (2008) 1.30
Protein profile of tax-associated complexes. J Biol Chem (2003) 1.28
Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology (2006) 1.25
Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochem (2002) 1.24
Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 1.21
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. J Virol (2008) 1.20
hnRNP A1: the Swiss army knife of gene expression. Int J Mol Sci (2013) 1.19
Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replication. J Biol Chem (2012) 1.18
Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29. J Virol (2008) 1.18
The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene (2005) 1.18
Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem (2004) 1.17
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem (2008) 1.17
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood (2009) 1.16
HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol (2012) 1.16
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer (2010) 1.16
Absence of DICER in monocytes and its regulation by HIV-1. J Biol Chem (2010) 1.15
HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem (2002) 1.15
Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II. J Biol Chem (2002) 1.14
Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One (2008) 1.13
The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci U S A (2003) 1.13
Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription. Retrovirology (2005) 1.13
Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr HIV Res (2003) 1.12
Nuclear protein phosphatase-1 regulates HIV-1 transcription. J Biol Chem (2003) 1.12
Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol (2010) 1.12
Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem (2005) 1.11
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Antimalarial drug discovery: targeting protein kinases. Expert Opin Ther Targets (2007) 1.11
Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J Biol Chem (2005) 1.10
Protein kinases as drug targets in parasitic protozoa. Trends Parasitol (2002) 1.10
Packaging and reverse transcription of snRNAs by retroviruses may generate pseudogenes. RNA (2004) 1.10
p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene (2002) 1.10
Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes. J Virol (2011) 1.09
Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene (2004) 1.07
Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr Opin Cell Biol (2013) 1.07
Protein phosphatase-1 activates CDK9 by dephosphorylating Ser175. PLoS One (2011) 1.06
Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol (2006) 1.06
Effect of transcription peptide inhibitors on HIV-1 replication. Virology (2008) 1.06
Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta (2004) 1.06
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle (2009) 1.06
Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Bioorg Med Chem (2006) 1.06
Synthesis and target identification of hymenialdisine analogs. Chem Biol (2004) 1.05
Ambient particulate matter directs nonclassic dendritic cell activation and a mixed TH1/TH2-like cytokine response by naive CD4+ T cells. J Allergy Clin Immunol (2006) 1.05
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem (2012) 1.04
Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J Med Chem (2008) 1.04
Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology (2012) 1.04